With Its Own Home, Pfizer Consumer Health Gets Higher Profile For Sale
This article was originally published in The Rose Sheet
Executive Summary
By setting up Pfizer Consumer Healthcare to have sales and earnings results reported separately, pharma giant could be making the division's assets more visible to potential buyers. Its sales pitch: "With a strong portfolio of global brands that span health and wellness, the company believes this business is well positioned to continue its growth."
You may also be interested in...
GSK Consumer In 2019: Start On Runway Toward Demerger For Deleveraging Debt
Glaxo's priority for its consumer business is regulatory approval, expected in the second half of 2019, of a JV with Pfizer announced in December so the segment will begin contributing meaningfully to GSK's growth. CEO Emma Walmsley says the JV plan with Pfizer is GSK's "most transformational announcement to date."
Pfizer Consumer Health True To Form Pending Move To JV With GSK
Pfizer consumer health sales up 4% to $3.6bn in 2018 as it prepares to move business into JV with GSK anticipated to close in the second half of 2019. Following 2% growth in 2017, a flat year in 2016 and a dip in 2015, Pfizer's view is confirmed of consumer health as a reliable revenue stream but not a strong growth driver.
Pfizer Consumer Health True To Form Pending Move To JV With GSK
Pfizer consumer health sales up 4% to $3.6bn in 2018 as it prepares to move business into JV with GSK anticipated to close in the second half of 2019. Following 2% growth in 2017, a flat year in 2016 and a dip in 2015, Pfizer's view is confirmed of consumer health as a reliable revenue stream but not a strong growth driver.